NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Gastroenterology and Mucosal Immunity > Research identifies how the gut loses protective barrier function in IBD

Research identifies how the gut loses protective barrier function in IBD

27 February 2019 · Listed under Gastroenterology and Mucosal Immunity

A University of Oxford research team has used single-cell technology to identify new players in the gut epithelial barrier, the single-cell layer that forms the lining of the small and large intestine.

The team from the MRC Human Immunology Unit (HIU), whose paper was published in the journal Nature, were supported by the NIHR Oxford Biomedical Research Centre.

Inflammatory Bowel Disease (IBD) affects at least 300,000 people in the UK, and its incidence is increasing worldwide, in particular in industrial-urbanised societies. There is no cure for IBD, and while many patients can manage the symptoms with appropriate care, around 40% of patients do not respond to available therapies.

Diseases such as IBD develop when the symbiotic relationship between the cells lining the surface of the gut wall and the trillions of bacteria that live inside the gut lumen breaks down.

Normally these bacteria are beneficial to our bodies, helping to digest food, training the immune system or preventing harmful bacteria from taking hold. However, in diseases such as IBD, the barrier cell layer that keeps these microorganisms inside the gut lumen breaks down, leading to emergence of harmful bacteria and subsequent inflammation.

To understand why this protective barrier breaks down, the MRC-HIU research team, led by Professor Alison Simmons, compared gut biopsies from healthy individuals and patients with IBD.

Prof Alison Simmons

Rather than looking at these biopsies as a whole, inferring the average behaviour of different types of cell in each sample, the researchers were interested in examining each cell individually, to understand how each one is changed in disease.

The team took advantage of the state-of-the-art single-cell facility at the MRC Weatherall Institute of Molecular Medicine to assemble a cell-by-cell map of the gut lining in health and IBD.

Using this careful analysis, researchers were able to identify a previously unknown sensor cell that can detect the level of acidity in the gut lumen.

They showed that these cells are located at the tip of the folds on the surface layer of the gut and secrete a hormone, uroguanylin, which regulates proliferation, metabolism and barrier function in the intestine on binding its ligand at acid pH. Surprisingly, these sensor cells were depleted in both IBD and colon cancer.

The researchers also examined the behaviour of barrier goblet cells. These cells play a pivotal role in secreting protective mucous over the colon surface to act as a block to an invasion of lumen bacteria.

Their analysis found several previously unknown subtypes of goblet cell, each with their own important function. The subtype that changed most dramatically in IBD normally produces an anti-bacterial substance. In IBD, this goblet cell type was damaged to such an extent, that it was unable to produce this anti-bacterial substance, leading to bacterial invasion and inflammation of the colon.

These results reveal a mechanism by which the gut stops being able to protect itself from luminal bacteria in patients with IBD.

This detailed analysis of the changes that happen to the gut in IBD opens new research opportunities; it provides the first insight, at single-cell level, of how the protective barrier of the gut keeps harmful bacteria at bay, and also how this barrier is disrupted in IBD.

“By identifying new colonic epithelial cell types and uncovering fundamental determinants of barrier breakdown in IBD we open up avenues to restore the protective mucus layer pharmaceutically” Prof Simmons, Professor of Gastroenterology in the Nuffield Department of Medicine, said.

“Our work is also the first time that we are able to understand how individual, single cells lining our gut change in inflammation and lose their ability to protect against the harmful effects of luminal microbes in IBD.”

As well as the Oxford BRC, this work was funded by the Medical Research Council, The Wellcome Trust and the NIHR.

← Study suggests immune system plays key role in survival after pancreatic cancer surgery
BRC researchers elected Fellows of Academy of Medical Sciences →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre